A recent study published in Scientific Reports has spotlighted a promising new approach to predicting outcomes and guiding treatment in colorectal cancer using neutrophil extracellular traps (NETs) as biomarkers. Researchers analyzed serum samples from 146 colorectal cancer (CRC) patients and 49 healthy controls, measuring levels of citrullinated histone H3 (CitH3)—a hallmark of NETs—by enzyme-linked immunosorbent assay (ELISA).
The team extracted NETs-related genes (NRGs) from the transcriptome data of neutrophils treated in vitro and developed a risk score model using LASSO regression. This NETs risk score proved itself as a strong predictor of patient prognosis, with area under the curve (AUC) values ranging from 0.745 to 0.762 for one- to five-year survival—impressive numbers in the world of cancer biomarkers. High-risk patients, as flagged by this model, showed significantly lower survival rates (p < 0.0001) and responded less effectively to chemotherapy.
NETs: Beyond Infection to Cancer Prognosis
Neutrophil extracellular traps, or NETs, are web-like structures released by neutrophils, primarily known for trapping pathogens. But recent evidence, like this study, links NETs to cancer metastasis and even chemotherapy resistance. Researchers are now exploring NETs both as targets for novel therapies and as real-world predictors of how patients will respond to treatment.
The findings are particularly relevant in CRC, a cancer type notorious for high mortality and variable outcomes. By identifying patients with high NETs risk scores, oncologists could potentially tailor chemotherapy regimens or explore alternative therapies sooner, offering a more personalized—and hopefully, more effective—approach.
While more validation is needed before NETs-based models enter routine clinical practice, these results point toward a future where a simple blood test could help steer major treatment decisions for colorectal cancer patients. That’s a leap forward in the ongoing quest to outsmart one of the world’s most stubborn cancers.
